Initial clinical trials of PARP inhibitors in gastric cancer showed mixed results, with a second-line regimen of Olaparib/paclitaxel showing benefit compared to paclitaxel/placebo in a molecularly unselected population, as well as in ATM deficient patients, in a phase 2 but not in the confirmatory phase 3 GOLD trial6,7. The gene discussed is PARP1; the disease is gastric cancer.